ÃâÒßѧÊÔÌâ
Z 4i5,f Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£©
m@+QC$6S 1. Fas(CD95)/FasL
~piE$"]& 2. common chain of cytokine receptor
l2YCl
K 3 . TCR/CD3 complex
r&B0-7r 4. negaive selection of thymocytes
Lu:*nJ%1[ 5. artificial active immune
MffCk!
] 6. anti-idiotypic
"crp/Bj? 7. IgSF
jO5R ~O` 8. Integrin
4
X7J~ 9. chemokine
,!alNNY 10. B7/CD28
zv0sz]) ¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²60·Ö£©
!sEhjJV^7 1. ±È½ÏMHC¢ñºÍMHC¢òÀ࿹ԲÎÓëµÄ¼Ó¹¤Ìá³Ê¿¹ÔµÄ¹ý³Ì¡£
\P9ms?((A 2. ±È½ÏCTLºÍNKɱÉ˰Ðϸ°ûʱʶ±ðºÍɱÉË»úÖÆµÄÌØµã¡£
_?cum~A@ 3. ±È½ÏÃâÒßѧ¼ì²â·¨ºÍÉúÎïѧ»îÐÔ¼ì²â·¨¼ì²âϸ°ûÒò×ÓµÄÓÅȱµã¡£ 4. ·¢ÏÖÒ»ÖÖеİ×ϸ°û·Ö»¯¿¹Ô»òÖ×ÁöÏà¹Ø¿¹Ô,²¢ÖƱ¸Á˵¥¿Ë¡¿¹Ìå,ÊÔÉè¼ÆÊµÑé·½°¸¿Ë¡´Ë»ùÒò¡£
QdcuV\B} 5. Ñ¡ÔñÏÂÊöÖÐÒ»¸öרÌâ,ÐðÊöÎÒ¹úÔÚÕâÒ»Ñо¿ÁìÓòµÄÏÖ×´¼°ÃæÁÙµÄÌôÕ½
hY%} x5ntU
^'M^0'_"v 1)Ö×ÁöÃâÒߣ»(2)»ùÒòÖÎÁÆ£»(3)CD¿¹Ô¡£
@RszPH1B µÚËľüÒ½´óѧһ¾Å¾ÅÆßÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÃâÒßѧÊÔÌâ
cN?/YkW?] Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£©
v=hn# U 1. B7/CD28
&0y`Gt 2. Th1 subset
~Js kA5h|& 3. seven predicated transmembrane domain receptor superfamily£¨STR superfamily£©
rO.[/#p\ 4. antibody affinity maturation
eD2eDxN2 5. AP-1
U9^1A* 6. single chain variable fragment£¨ScFv£©
3 )#Nc| 7. NK cell receptor
`[#id@Z1 8. Zinkernagel-Doherty phenomenon
TIl
'Z7 9. Ig fold
9$e$L~I#u 10. CD40/CD40L
7=u
Gf$/ ¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²36·Ö£©
-ZSN0Xk 1. ÊÔÊöÐØÏÙ΢»·¾³¶ÔÐØÏÙϸ°ûµÄÑ¡Ôñ×÷Óü°ÆäÓëTϸ°û¹¦ÄÜÐÔÑÇȺÐγɵĹØÏµ¡£
@#N7M2/ 2. ÊÔÊöÌåÒºÃâÒßÓ¦´ðµÄ¹æÂÉ£¬»ØÒä·´Ó¦ºÍ¿¹ÌåÀà±ðת»»µÄ»úÖÆÊÇʲô£¿
# |(>UM\ 3. ÊԴӽṹºÍ¹¦ÄܵȽǶȣ¬²ûÊö°×ϸ°û·Ö»¯¿¹Ô£¨CD£©¡¢Õ³¸½·Ö×Ó£¨integrin£©ºÍÃâÒßÇòµ°°×³¬¼Ò×壨IgSF£©ÈýÀà·Ö×ÓµÄÏ໥¹ØÏµ¡£Ä¿Ç°ÔÚÕâÒ»ÁìÓòÖÐÖ÷ÒªÑо¿ÈȵãÊÇʲô£¿
G'}N ?8s1 Èý. ÎÊ´ðÌ⣨24·Ö£¬µÚ1ÌâΪÃâÒßѧרҵ¿¼ÉúÊÔÌ⣬µÚ2ÌâΪѪҺ²¡Ñ§¿Æ¿¼ÉúÊÔÌ⣬µÚ3ÌâΪÏû»¯ÄÚ¿Æ¿¼ÉúÊÔÌ⣬ֻÔÊÐí´ð±¾×¨ÒµÊÔÌ⣩
:7"Q 1. ÊԱȽÏTCRºÍBCR½á¹¹¼°Æäʶ±ð¿¹Ô¡¢ÁܰÍϸ°û»î»¯ÐźŵķÖ×Ó»úÀí¡££¨ÃâÒßѧרҵ£©¡£
(tVT&eO 2. ÊÔÊö°×Ѫ²¡ÃâÒßѧ·ÖÐÍÀíÂۺͷ½·¨µÄÑо¿½øÕ¹¡££¨ÑªÒº²¡Ñ§×¨Òµ£©¡£
{5X,xdzR 3. ÊÔÊöÖ×ÁöÒßÃçµÄÑо¿½øÕ¹¡££¨Ïû»¯ÄÚ¿Æ×¨Òµ£©¡£
6s~B2t:Y Ò»¾Å¾Å°ËÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ
$.d,>F6 £¨ÃâÒßѧרҵºÍרҵ»ù´¡£©
Keo<#C
c? Ò».Ãû´Ê½âÊÍ£¨Ã¿Ìâ3·Ö£¬¹²45·Ö£©
zng.(]U/?H 1.Co-stimulators (or co-stimulating molecules)
'm6bfS^T 2.NK-kB
bfoTGi
3.Immunoglobulin superfamily
u<fZ.1 4.antigen-presenting cell (APC)
^W:a7cMw 5.death domain
#;^U
W 6.CCR and CXCR
=Hd#"9- 7.Lectin (or mitogen)
V?G%-+^ 8.Clusters of differentiation, CD)
6=$<
R4B 9.B7 family
F09%f"9 10.Cytotoxic T lymphocyte, CTL)
1`L.$T,1! 11.IL-15 and IL-15 receptor (IL-15R)
)LKJfoo
PY 12.MHC restriction
E%D .a=UX, 13.Affinity-chromatography
cf,6";8 14.Cyctosprin A, CsA
&Lt$~}*&6 15.Antibody-dependent cell-mediated cytotoxicity, ADCC)
Bx5xtJ|! ¶þ.ÎÊ´ðÌ⣨ÿÌâ10·Ö£¬¹²30·Ö£©
xcmg3:s 1.ºÎΪTh1ºÍ Th2ÑÇȺ£¿ÈçºÎ¼ì²â£¿ÔÚÁÙ´²ÉÏÓкÎÒâÒ壿
579D 2.ÊÔÊöÃâÒßÇòµ°°×£¨Ig£©µÄ½á¹¹Ó빦ÄܵĹØÏµ¡£
2>k*9kyp 3.ÊԱȽÏTϸ°ûÊÜÌ壨TCR/CD3£©ÓëBϸ°ûÊÜÌ壨BCR£©µÄ×é³É¡¢½á¹¹¼°Æäʶ±ð ¿¹ÔµÄÌØµã¡£
j?|Vx' Èý.Ñ¡ÔñÎÊ´ðÌ⣨¸÷רҵ¿¼ÉúÖ»´ðÒ»µÀ±¾×¨ÒµÊÔÌ⣬25·Ö£©
:fL7"\
pf~ ÃâÒßѧרҵ£º
]nRf%Vi8g 1.ÊÔÊöB7/CD28, CTLA-4£¬CD40/CD40L£¬LFA-1/ICAM-1£¬CD2/LFA-3µÄ½á¹¹¡¢·Ö²¼ÒÔ¼°Ï໥×÷Óúó½éµ¼µÄÖ÷ÒªÉúÎïѧ¹¦ÄÜ¡£
H^S<bZ Ïû»¯ÄÚ¿Æ£º
^1Fzs(#. 2.Ö×Áö¿¹Ô·ÖΪÄļ¸Àࣿ»úÌ忹Ö×ÁöÃâÒßÖ÷ÒªÓÐÄÄЩÒòËØ£¨»úÖÆ£©£¿¼òÊöÌá¸ß¿¹Ö×ÁöÃâÒßÑо¿µÄÂԲߡ£
,qp
8Rg|3j ѪҺ²¡Ñ§×¨Òµ£º
."BXA8c;A 3.ºÎΪ°×Ѫ²¡µÄÃâÒßѧ·ÖÐÍ£¿ºÎÎªÒÆÖ²ÎËÞÖ÷·´Ó¦£*****VHR£©£¿GVHR·¢ÉúµÄÖ÷ÒªÔÒò£¨Ìõ¼þ£©ÊÇʲô£¿
*Us}E7/"' Ò»¾Å¾ÅÄê¾Å²©Ê¿ÉúÈëѧ¿¼ÊÔÊÔÌâ
%
au>D (רҵ»ù´¡: ÃâÒßѧ)
965 x_
% Ò».Ãû´Ê½âÊÍ(ÿÌâ5·Ö,¹²45·Ö)
Myg;2 . 1. ADCC(antibody dependent cell-mediated cytotoxicity)
,|VLOY^ 2. »·æß¾úËØ(cyclosporin)
q#c+%,Z=C 3. KIR(killer cell inhibitory receptor)
OwNM`xSa|\ 4. HLDA(human leucocyte differentiation antigen)
Y(1?uVYW\d 5. Interleukin 18(IL-18)
vO9=CCxvq 6. ÕûºÏËØ(integrin)
I
Z>l 7. Fas/FasL
C&qo$C 8. FcR(ÃâÒßÇòµ°°×Fc¶ÎÊÜÌå)
&W<9#RPK' 9. ϸ°û¼äÕ³¸½·Ö×Ó(ICAM)
K7JZUS`C! 10. Th1/Th2
yZp/P %y 11. »ùÒòÒßÃç(DNAÒßÃç)
:qj^RcmVPL 12. chemokines and chemokine receptor
Oj%5FUP~[% 13. ÃâÒßÄÍÊÜ
T`]%$$1s 14. ¹²´Ì¼¤·Ö×Ó
`0U\|I# 15. ËÀÍö½á¹¹Óò(death domain)
L58H)V3Pn ¶þ.ÎÊ´ðÌâ(µÚ1¡¢2Ìâ¸÷18·Ö,µÚ3Ìâ19·Ö)
p JF
9Z 1. ÊԱȽÏɱÉËÐÔTϸ°û(CTL)Óë×ÔȻɱÉËϸ°û(NK)ÔÚɱÉ˰Ðϸ°û¹ý³ÌÖÐ,ʶ±ðϸ°û¶¾¼°½éµ¼ÃâÒß¹¦ÄÜÓкβ»Í¬?
7n84`|= 2. 70Äê´úÒÔÀ´,ÓйØIgºÍÌåÒºÃâÒßÑо¿´æÔÚÒÔϼ¸ÏîÖØ´ó·¢ÏÖºÍÍ»ÆÆ¶ø»ñµÃҽѧºÍÉúÎïѧŵ±´¶û½±,Çë·Ö±ð²ûÊöËüÃǵÄÀíÂÛÒâÒå¼°ÔÚҽѧʵ¼ùÖеÄÓ¦Óá£
pO)EYla9 £¨1£©1972Ä꣺θµ°°×øºÍľ¹Ïµ°°×øˮ½âIg£¬»ñµÃFab¡¢Fc¡¢F£¨ab¡¯£©2µÈƬ¶Î
N\tFK*U^I £¨2£©1977Ä꣺·ÅÉäÃâÒß·¨
fHZ9wK> £¨3£©1984Ä꣺ÁܰÍϸ°ûÔÓ½»ÁöºÍµ¥¿Ë¡¿¹Ìå
fA
TVAv £¨4£©1987Äê: Ig»ùÒòµÄ½á¹¹
85dC6wI4K 3. ½üÄêÀ´ÔÚÖ×ÁöÃâÒßÑо¿ÁìÓòÖÐÓÐÄÄÐ©ÖØÒª½øÕ¹?ÊÔÊöµ±Ç°Ìá¸ß»úÌ忹Ö×ÁöÃâÒßµÄÖ÷Òª²ßÂÔ¡£
^vSSG5 : Ò»¾Å¾Å¾ÅÄ격ʿÉúÈëѧ¿¼ÊÔÊÔÌâ(ÃâÒßѧרҵ)
-"'+#9{h ÎÊ´ðÌâ(ÿÌâ25·Ö)
g^|R;s{ 1. ÊԱȽÏTϸ°ûÊÜÌ壨TCR£©¡¢Bϸ°ûÊÜÌ壨BCR£©ºÍNKϸ°ûÊÜÌ壨NKCR£©µÄ×é³É£¬Ê¶±ðÅäÌåÒÔ¼°ÐźÅתµ¼µÄÒìͬµã¡£
g&w~eWpk 2. ÒÔÐØÏÙÒÀÀµ¿¹Ô´Ì¼¤»úÌå²úÉú¿¹ÌåµÄÃâÒßÓ¦´ðΪÀý£¬Tϸ°ûºÍBϸ°ûÊÇÈçºÎÏ໥×÷Óã¿ÓÐÄÄЩճ¸½·Ö×Ӻ͹²´Ì¼¤·Ö×Ó²ÎÓëT¡¢Bϸ°ûµÄÏ໥×÷Óã¿
58HAl_8W 3. Éö×ÛºÏÕ÷³öѪÈÈ(HFRS)²¡¶¾µÄ½á¹¹»ùÒòÒѾ¸ãÇå³þ,ΪÁË֤ʵHFRS²¡¶¾¸ÐȾ»úÌå(ÒÔBalb/CСÊóΪÀý)¿É²úÉúHFRS²¡¶¾ºËÒ¿ǵ°°×(NP)ÌØÒìÐÔCTL,²¢ÔÚÃâÒß·À»¤ÖÐÆðÖØÒª×÷ÓÃ,ÇëÓ¦ÓÃÃâÒßѧÀíÂۺͷ½·¨,Éè¼ÆÒ»ÏµÍ³ÊµÑé,¼ÓÒÔ֤ʵ¡£
(
6zu*H) 4. Àý¾Ù¶þ¸ö½üÄêÀ´Ï¸°ûºÍ·Ö×ÓÃâÒßѧÑо¿ÖгöÏÖµÄеÄÈȵã,Çë·Ö±ðÆÀÊöÆäÑо¿ÒâÒå¡¢·¢Õ¹Ç÷ÊÆÒÔ¼°Ó¦ÓÃǰ¾°¡£